research use only

Hydroquinone ROS chemical

Name: Hydroquinone
Brand: Selleck Chemicals
SKU: S4580
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S4580

Hydroquinone (Quinol, 1,4-Benzenediol, 1,4-Dihydroxybenzene, HQ) is a Melanin Synthesis Inhibitor. The physiologic effect of hydroquinone is by means of Depigmenting Activity. It also posesses antioxidant properties that can cause toxicity in several organs, notably the kidney.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.

Chemical Structure

Molecular Weight: 110.11

Jump to

Quality Control

Batch: S458001 DMSO]22 mg/mL]false]Water]22 mg/mL]false]Ethanol]22 mg/mL]false Purity: 99.93%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.93

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other ROS Inhibitors	MitoQ (Mitoquinone) Mesylate Piperlongumine H2DCFDA (DCFH-DA) Gallic acid Neohesperidin Idebenone (20R)Ginsenoside Rg3 Pyrogallol Troxerutin Asiaticoside

Solubility

In vitro
Batch:

DMSO : 22 mg/mL (199.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 22 mg/mL

Ethanol : 22 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	110.11	Formula	C₆H₆O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	123-31-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Quinol, 1,4-Benzenediol, 1,4-Dihydroxybenzene, HQ			Smiles	C1=CC(=CC=C1O)O

Mechanism of Action

In vitro	At 50 µM HQ(Hydroquinone), R-28 cells show a significant decrease in cell viability compared with the dimethyl sulfoxide (DMSO)-treated controls. At the 100–500 µM concentrations, all three cell lines show significant cell death (P <0.001). In the ARPE-19, R-28, and HMVEC cultures, the caspase-3/7 activities are not increased at any of the HQ concentration. Neuroretinal R-28 cells are more sensitive to HQ than the ARPE-19 and HMVEC cultures.
In vivo	In vivo exposure of rats to HQ results in changes of immune response mirrored by impairing allergic lung response to ovalbumin, an antigen unrelated to HQ. HQ exposure impairs the expression of CD45R and CD6 co-stimulatory molecules on activated spleen lymphocytes and diminishes the levels of OA(ovalbumin)-anaphylactic antibodies and the subsequent mast cell degranulation in sensitized rats challenged with OA.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22569379/ [2] https://pubmed.ncbi.nlm.nih.gov/17897770/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06366464	Recruiting	Prader-Willi Syndrome	Harmony Biosciences LLC	April 30 2024	Phase 3
NCT06297447	Recruiting	Musculoskeletal Pain\|Chronic Pain	Bettina Eiger\|University of Southern Denmark\|Aalborg University\|Central Denmark Region\|Vrije Universiteit Brussel	March 11 2024	Not Applicable
NCT06275386	Not yet recruiting	Coronary Artery Disease\|Total Occlusion of Coronary Artery	National Institute of Cardiology Warsaw Poland	March 1 2024	Not Applicable
NCT06193499	Recruiting	Osteoarthritis Thumb	Karolinska Institutet	January 17 2024	Not Applicable
NCT06173531	Recruiting	Hyperphagia in Prader-Willi Syndrome	ACADIA Pharmaceuticals Inc.	November 27 2023	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):